This clinical trial, sponsored by Pfizer in collaboration with Arvinas Estrogen Receptor, Inc., targets a significant unmet need in the treatment of advanced or metastatic ER+/HER2- breast cancer, a prevalent and challenging cancer subtype. The combination therapy aims to improve patient outcomes by leveraging novel mechanisms of action. If successful, this could position Pfizer favorably in the competitive landscape of breast cancer therapeutics, particularly against existing SERDs and CDK4/6 inhibitors. The trial's outcomes may also influence future market strategies and partnerships, particularly in the context of personalized medicine approaches in oncology.